H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cormedix (CRMD) today and set a price target of $10.00. The company’s shares closed last Friday at $5.69.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 19.4% and a 56.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies, Springworks Therapeutics, and Protalix Biotherapeutics.
Cormedix has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.97 and a one-year low of $2.16. Currently, Cormedix has an average volume of 422.1K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
